drugset / Trial / NCT00022958
Expanded Access Study of Iodine-131 Anti-B1 Antibody
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on the efficacy and safety of Iodine-131 Anti-B1 Antibody.
Timeline
- Start
- 1998-09
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TOSITUMOMAB 131I | Monoclonal antibody | — | — |